About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:2675764
Allelic
Composition
Drd2tm1Ebo/Drd2tm1Ebo
Genetic
Background
involves: 129S2/SvPas * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Drd2tm1Ebo mutation (0 available); any Drd2 mutation (70 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
N
• homozygotes exhibit a normal exploratory response in a stressful (highly illuminated) open field with unknown objects relative to wild-type controls
• in response to morphine administration (2 and 6 mg/kg body weight), homozygous mutant and wild-type mice show a similar increase in horizontal locomotor activity under non-stressful conditions
• in response to endogenous opioid administration (RB 101, 100 mg/kg body weight), homozygous mutant and wild-type mice show a similar increase in horizontal locomotor activity relative to saline-treated controls, indicating normal opioid-induced hyperlocomotion
• following chronic administration of increasing doses of morphine , homozygotes show no differences in the incidence of naloxone-precipitated somatic signs of morphine withdrawal relative to similarly treated wild-type controls
• in a non-selective attention test, mice exhibit higher scanning times (measured by duration of individual rearing episodes) during the second part of the test compared with wild-type mice
• at 10 mg/kg kainic acid (i.p.), homozygotes display preconvulsive behaviors (rigid posture, tail stiffening, and forelimb extension) whereas wild-type and heterozygotes remain immobile
• at 20 mg/kg kainic acid, homozygotes exhibit obvious symptoms of limbic epileptic activity (repeated episodes of rearing with forelimb clonus, alternating with rigid posture and head bobbing), whereas wild-type and heterozygous controls display only preconvulsive signs
• however, at 35 mg/kg kainic acid, homozygotes exhibit repeated limbic seizures of the same severity as those observed in wild-type and heterozygous controls
• in response to s.c. morphine administration (3 mg/kg body weight), homozygotes, unlike wild-type controls, fail to display a significant increase in the time spent in the morphine-associated compartment during the testing phase of a conditioned place preference paradigm, indicating that opioid rewarding properties are suppressed
• in response to a higher morphine dose (9 mg/kg body weight), drug-naive homozygotes also fail to show place preference in the same place-conditioning paradigm, indicating lack of a developed tolerance to endogenous opioids
• however, morphine-treated homozygotes display a behavior similar to that of wild-type controls during the preconditioning phase of the place-conditioning paradigm, and retain a normal exploratory activity and locomotor response to morphine treatment
• homozygotes show a normal conditioned place preference when palatable food is used as reward, indicating that the motivational deficit affects morphine rewarding properties but not natural rewards
• homozygotes display a 10-15% reduction in water intake relative to wild-type mice
• homozygotes display a 10-15% reduction in food intake relative to wild-type mice
• homozygotes spend significantly less time on the rotarod than heterozygous or wild-type mice
• homozygotes display an abnormal posture, with fore- and hindpaws flattened to the ground
• when allowed to walk on a flat surface, homozygotes display an abnormal gait, with sprawled hind legs
• homozygotes exhibit no vertical activity (rearing) in the open-field test (J:29045)
• homozygotes show a significant reduction in locomotion (74%) and backward movements in the open-field test (J:29045)
• homozygotes show normal reflexes but exhibit slower movements relative to wild-type littermates
• homozygotes display a cataleptic-like behavior as quantified in the ring test

endocrine/exocrine glands
• unlike in wild-type mice, the mutant zonae fasciculata and reticularis are fused in mutant mice
• unlike in wild-type mice, the mutant zonae fasciculata and reticularis are fused in mutant mice
• at 4 months of age, homozygotes exhibit significant adrenocortical hypertrophy with the characteristic fusion of the zona fasciculata and reticularis seen in patients with Cushing's syndrome
• at 4 months of age, homozygotes exhibit significant adrenocortical hyperplasia relative to wild-type controls
• at 4 months of age, prolactin-positive cells appear smaller and more compact than normal
• at 4 months of age, female homozygotes show an increased number of lactotrophs relative to wild-type controls
• aberrant proliferation of lactotrophs gives rise to tumors in aged mice
• at 4 months of age, female homozygotes show a 25% decrease in the number of GH-expressing cellls relative to wild-type controls
• at 4 months of age, female homozygotes show a 2-fold increase in thyrotroph cell number relative to wild-type controls
• however, plasma beta-TSH levels are not significantly increased
• at 4 months of age, the anterior lobe of female mutant pituitaries shows an increase in both cell number and density relative to that in wild-type controls
• at 4 months of age, homozygotes of both sexes display an enlarged pituitary
• however, pituitary enlargement is less pronounced in males
• mutant pituitaries show absence of dopaminergic control (sites) resulting in pituitary cell proliferation
• male homozygotes display less prominent pituitary gland hyperplasia than age-matched female homozygotes
• hyperplasia appears to correlate with a progressive induction of prolactin receptor levels in the pituitary gland as homozygotes become older
• whereas hyperplasia of the intermediate lobe occurs earlier (7-8 weeks of age) and remains contained even in aged animals, hyperplasia of the anterior lobe is delayed (3-4 months) but progressive leading to tumors in aged mice
• at 4 months of age, homozygotes display both increased melanotroph proliferation and altered cellular identity
• at 4 months of age, intermediate lobe hyperplasia is due to increased proliferation of POMC-producing melanotrophs (J:110599)
• at 4 months of age, the intermediate lobe of female mutant pituitaries shows a 40% increase in cell number, but not in cell density, relative to that in wild-type controls (J:41857)
• at 8-14 months of age, all female homozygotes display anterior pituitary tumors with nodular areas and large blood vessel infiltration
• male homozygotes develop anterior pituitary tumors much later than female homozygotes (19 months versus 8 months of age, respectively)
• at 4 months of age, homozygotes display adrenal hypersecretion of corticosterone due to excess circulating ACTH levels
• at 4 months of age, homozygotes show a 2-fold increase in POMC expression that is specifically restricted to pituitary melanotrophs
• mutant melanotrophs lose their cell identity and display aberrant production of ACTH leading to adrenal hyperplasia
• however, expression of the hypothalamic corticotropin releasing hormone (CRF) involved in the regulation of POMC synthesis remains unaffected

growth/size/body
• homozygotes exhibit a 15% reduction in body weight relative to wild-type mice

homeostasis/metabolism
• at 16 hrs after 20 or 35 mg/kg kainic acid administration, homozygotes, but not wild-type controls, display induction of Jun mRNA and the proapoptotic factor BAX, as well as fragmented DNA in CA3 cells and an increased number of TUNEL-positive cells, suggesting hippocampal cell death by apoptosis
• the extension of BAX labeling and tissue damage in the CA3 subfield are larger than that of TUNEL staining, indicating progressive apoptotic hippocampal cell death after kainic acid-induced seizures
• cell loss is detected only in the CA3 subfield but not in other regions of the hippocampus
• an extensive gliosis is observed in the CA3 subfield by GFAP immunohistochemistry
• the extent of CA3 cell damage following treatment with 35 mg/kg kainic acid is greater than that observed with 20 mg/kg, indicating a dose-dependent toxic effect; a higher number of TUNEL-positive cells and a larger extension of reactive gliosis are additionally observed in homozygotes treated with 35 mg/kg
• at 12 hrs after 35 mg/kg kainic acid administration, homozygotes show a stronger Jun induction in the hippocampus and cerebral cortex than wild-type controls, correlating with the occurrence of hippocampal cell death
• female homozygotes show a 70% reduction in serum estrogen levels relative to wild-type females
• male homozygotes display a 20% reduction in serum estrogen levels relative to wild-type males
• interestingly, female and male homozygotes display very similar serum estrogen levels (8 ng/l and 9 ng/ml, respectively)
• at 4 months of age, homozygotes show a 1.5-fold increase in plasma corticosterone levels relative to wild-type controls
• at 4 months of age, plasma GH levels are reduced by 25% and 35% in male and female homozygotes, respectively
• at 4 months of age, homozygotes show a 5.7- and 2.7-fold increase in serum levels of beta-endorphin and alpha-MSH, respectively, relative to wild-type controls
• in the absence of dopaminergic control, adult homozygotes show 10.9- and 5.3-fold higher serum prolactin levels in females and males, respectively, relative to wild-type controls
• female homozygotes show a 6-fold rise in plasma prolactin levels relative to male homozygotes (264 +/- 35.2 ng/ml versus 41.1 +/- 7.2 ng/ml, respectively), whereas wild-type females show only a 3-fold difference in prolactin levels relative to wild-type males
• unexpectedly, 4-month-old homozygotes show a 4-fold increase in serum ACTH levels relative to wild-type controls
• increased ACTH levels are due to aberrant processing of the POMC propeptide in melanotrophs, as shown by a 4- to 5-fold increase in expression of prohormone convertase Pcsk1 (PC1) in the intermediate lobe of mutant mice
• homozygotes exhibit a 0.7 degree C reduction in body temperature relative to wild-type mice

reproductive system
• female homozygotes display an abnormal estrous cycle
• female homozygotes display a prolonged diestrus, as shown by the continued presence of lymphocytes in vaginal fluid
• a recognizable estrus is observed only once a month instead of every 4 days
• litters can only be obtained by breeding homozygous mutant mice with their heterozygous counterparts
• female homozygotes display impaired gonadal function due to hyperprolactinemia
• in contrast, male homozygotes exhibit normal spermatogenesis

nervous system
• at 10 mg/kg kainic acid (i.p.), homozygotes display preconvulsive behaviors (rigid posture, tail stiffening, and forelimb extension) whereas wild-type and heterozygotes remain immobile
• at 20 mg/kg kainic acid, homozygotes exhibit obvious symptoms of limbic epileptic activity (repeated episodes of rearing with forelimb clonus, alternating with rigid posture and head bobbing), whereas wild-type and heterozygous controls display only preconvulsive signs
• however, at 35 mg/kg kainic acid, homozygotes exhibit repeated limbic seizures of the same severity as those observed in wild-type and heterozygous controls
• at 4 months of age, prolactin-positive cells appear smaller and more compact than normal
• at 4 months of age, female homozygotes show an increased number of lactotrophs relative to wild-type controls
• aberrant proliferation of lactotrophs gives rise to tumors in aged mice
• at 4 months of age, female homozygotes show a 25% decrease in the number of GH-expressing cellls relative to wild-type controls
• at 4 months of age, female homozygotes show a 2-fold increase in thyrotroph cell number relative to wild-type controls
• however, plasma beta-TSH levels are not significantly increased
• at 4 months of age, the anterior lobe of female mutant pituitaries shows an increase in both cell number and density relative to that in wild-type controls
• at 4 months of age, homozygotes of both sexes display an enlarged pituitary
• however, pituitary enlargement is less pronounced in males
• mutant pituitaries show absence of dopaminergic control (sites) resulting in pituitary cell proliferation
• male homozygotes display less prominent pituitary gland hyperplasia than age-matched female homozygotes
• hyperplasia appears to correlate with a progressive induction of prolactin receptor levels in the pituitary gland as homozygotes become older
• whereas hyperplasia of the intermediate lobe occurs earlier (7-8 weeks of age) and remains contained even in aged animals, hyperplasia of the anterior lobe is delayed (3-4 months) but progressive leading to tumors in aged mice
• at 4 months of age, homozygotes display both increased melanotroph proliferation and altered cellular identity
• at 4 months of age, intermediate lobe hyperplasia is due to increased proliferation of POMC-producing melanotrophs (J:110599)
• at 4 months of age, the intermediate lobe of female mutant pituitaries shows a 40% increase in cell number, but not in cell density, relative to that in wild-type controls (J:41857)
• at 8-14 months of age, all female homozygotes display anterior pituitary tumors with nodular areas and large blood vessel infiltration
• male homozygotes develop anterior pituitary tumors much later than female homozygotes (19 months versus 8 months of age, respectively)
• at 4 months of age, homozygotes show a 2-fold increase in POMC expression that is specifically restricted to pituitary melanotrophs
• mutant melanotrophs lose their cell identity and display aberrant production of ACTH leading to adrenal hyperplasia
• however, expression of the hypothalamic corticotropin releasing hormone (CRF) involved in the regulation of POMC synthesis remains unaffected
• at 3 hrs after kainic acid treatment (20 mg/kg), homozygotes show a strong and widespread Fos expression throughout the entire brain, whereas wild-type controls display a reduced labeling that is primarily restricted to the hippocampus
• at 6 hrs after kainic acid treatment (20 mg/kg), homozygotes exhibit sustained Fos expression in the hippocampus and cerebral cortex, whereas no labeling is detected in wild-type controls
• at 6 hrs after kainic acid treatment (20 mg/kg), homozygotes, but not wild-type controls, exhibit a robust Jun induction in the dentate gyrus, and hippocampal CA1 nd CA3 regions
• at 16 hrs after 20 or 35 mg/kg kainic acid administration, homozygotes, but not wild-type controls, display induction of Jun mRNA and the proapoptotic factor BAX, as well as fragmented DNA in CA3 cells and an increased number of TUNEL-positive cells, suggesting hippocampal cell death by apoptosis
• the extension of BAX labeling and tissue damage in the CA3 subfield are larger than that of TUNEL staining, indicating progressive apoptotic hippocampal cell death after kainic acid-induced seizures
• cell loss is detected only in the CA3 subfield but not in other regions of the hippocampus
• an extensive gliosis is observed in the CA3 subfield by GFAP immunohistochemistry
• the extent of CA3 cell damage following treatment with 35 mg/kg kainic acid is greater than that observed with 20 mg/kg, indicating a dose-dependent toxic effect; a higher number of TUNEL-positive cells and a larger extension of reactive gliosis are additionally observed in homozygotes treated with 35 mg/kg
• at 12 hrs after 35 mg/kg kainic acid administration, homozygotes show a stronger Jun induction in the hippocampus and cerebral cortex than wild-type controls, correlating with the occurrence of hippocampal cell death

neoplasm
• at 8-14 months of age, all female homozygotes display anterior pituitary tumors with nodular areas and large blood vessel infiltration
• male homozygotes develop anterior pituitary tumors much later than female homozygotes (19 months versus 8 months of age, respectively)

pigmentation
• at 4 months of age, homozygotes display coat hyperpigmentation due to increased alpha-MSH and ACTH levels

cellular
• at 16 hrs after 20 or 35 mg/kg kainic acid administration, homozygotes, but not wild-type controls, display induction of Jun mRNA and the proapoptotic factor BAX, as well as fragmented DNA in CA3 cells and an increased number of TUNEL-positive cells, suggesting hippocampal cell death by apoptosis
• the extension of BAX labeling and tissue damage in the CA3 subfield are larger than that of TUNEL staining, indicating progressive apoptotic hippocampal cell death after kainic acid-induced seizures
• cell loss is detected only in the CA3 subfield but not in other regions of the hippocampus
• an extensive gliosis is observed in the CA3 subfield by GFAP immunohistochemistry
• the extent of CA3 cell damage following treatment with 35 mg/kg kainic acid is greater than that observed with 20 mg/kg, indicating a dose-dependent toxic effect; a higher number of TUNEL-positive cells and a larger extension of reactive gliosis are additionally observed in homozygotes treated with 35 mg/kg
• at 12 hrs after 35 mg/kg kainic acid administration, homozygotes show a stronger Jun induction in the hippocampus and cerebral cortex than wild-type controls, correlating with the occurrence of hippocampal cell death


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory